Latest News & Features
Refine Search
Big Pharma
 Clarivate study highlights treatments with blockbuster potential | IV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer make the list | Nine blockbusters from China also predicted.   12 January 2023 
Americas
 Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.   10 January 2023 
article
 German IP specialist gears up for UPC with experienced partner | Patent litigator previously led practice at IP boutique Meissner Bolte.   10 January 2023 
Genetics
 Science fiction is becoming science fact but the Alice/Mayo framework throws up some interesting challenges to bringing life back from the dead, explains Brian Hausman of Baker Botts.   5 January 2023 
Europe
 ‘Rare’ case included ‘campaigning element’ says judge | Ex-student sought clarification on royalties from university | 651-paragraph ruling required Oxford Uni to justify its IP policies.   5 January 2023 
Americas
 Distributors and pharmacies face millions in damages and costs after selling international versions of Abbott products in the US | Fraud upon the court discovered after a court-authorised search of defendant’s premises seized an email server.   4 January 2023 
Medtech
 Bringing a medical device to market relies on a broad understanding of IP, explain Sabing Lee and Kregg Koch of Knobbe Martens.   3 January 2023 
Big Pharma
 California-based company alleges competitor stole secrets following a collaboration bid | Complaint says Chinese competitor founded a sister company to develop rival treatment for metabolic disorders.   3 January 2023 
Americas
 Addition is a former chair of a patent practice group | New partner has expertise in complex disputes over medical devices | Barnes & Thornburg | Patterson Thuente Pedersen.   22 December 2022 
Big Pharma
 Counterfeit medicine and drugs cause more than one million deaths a year | Trio of bodies will work jointly  together | National Intellectual Property Rights Coordination Center | Homeland Security Investigations.   22 December 2022 


